Introduction
We previously created a model of acute promyelocytic leukemia (APL) in transgenic animals by targeting the expression of a human bcr-1 isoform of PML-RARα cDNA to early myeloid cells using regulatory sequences from the human cathepsin G (hCG) gene. 1 All mice expressing this transgene develop a myeloproliferative disease, but only ~15-30% of mice develop APL (after a latency of 6-13 months). 1 RARα-PML reciprocal translocation products are expressed in up to 80% of patients with APL. 2, 3 The bcr-1 isoform of RARα-PML results from the fusion of RARα at intron 2 with PML at intron 6, while the bcr-3 isoform of RARα-PML fuses RARα at intron 2 with PML at intron 3 ( Figure 1A ). Mice that co-express the reciprocal human bcr-3 isoform
RARα-PML cDNA in the same early myeloid compartment as the bcr-1 isoform of PML-RARα display an APL penetrance of ~60% (with the same latency). 4 Most APL tumors that develop in mice expressing both transgenes acquire an interstitial deletion on one copy of chromosome 2
For personal use only. on . by guest www.bloodjournal.org From (del(2)). 5 The importance of del(2) as a progression factor in murine APL has been further supported by the association of del(2) with radiation-induced AML, and the increased penetrance of APL observed after irradiating young PML-RARα expressing mice (which also induces del(2)). 6, 7 These data suggest that the expression of a bcr-3 RARα-PML fusion gene, or exposure to irradiation, facilitates the development of del(2) in PML-RARα expressing mice.
The minimal del(2) interval defined to date contains the PU.1 gene, which is directly relevant for AML pathogenesis. 6, [8] [9] [10] [11] [12] [13] In our original study, a bcr-3 isoform of RARα-PML was chosen because of its ready availability, and because it contains a large amount of sequence from PML (including its nuclear localization signal and a Rb interacting domain 14 ). However, since it is not the reciprocal translocation partner of bcr-1 PML-RARα, we have now expressed a bcr-1 reciprocal in mice, using the same human cathepsin G targeting cassette. The lack of a phenotype indicates that different reciprocal isoforms may have different biologic functions that are relevant for the pathogenesis of APL in mice.
Materials and Methods
We have previously described the generation of bcr-1 hCG-PML-RARα and bcr-3 hCG-RARα-PML transgenic mice in the C3H x C57Bl/6 background. washing, scanning and analysis were performed as previously described.
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Results and Discussion
We have reported previously the phenotype of transgenic animals co-expressing a bcr-3 isoform of RARα-PML with a bcr-1 isoform of PML-RARα. 4 To define the biologic role of a bcr-1 isoform of RARα-PML, we inserted this cDNA into our standard hCG regulatory cassette at the ClaI-NotI site in the 5'UT. We identified 2 founder mice that transmitted the transgene through the germline (lines 9 and 11). The level of bcr-1 RARα-PML mRNA expression in whole bone marrow samples from transgenic mice was similar to that of PML-RARα expression (relative expression compared to PML-RARα: line 9 = 0.78, line 11 = 2.72), which was similar to the level of bcr-3 RARα-PML expression previously reported. 4 Transgene expression levels in the bone marrow of doubly transgenic animals were appropriately increased compared to PML-RARα or bcr-1 RARα-PML expressing mice alone.
Bcr-1 RARα-PML (RP1) mice have normal peripheral blood counts compared to their age- PRxRP1, p=0.19 ). The second intercross (line 11) is less mature than the first intercross, but the results are similar; there was no significant difference in APL development in PR animals (8/22) compared to PRxRP1 animals (14/33) after 12 months of observation (p=0.5). The peripheral blood counts and splenic morphology of APL cells were similar for PR and PRxRP1 animals (data not shown).
We next analyzed cells derived from the spleens of leukemic animals for the presence of del (2) using array-based comparative genomic hybridization (aCGH). The frequency of del(2) could not be assessed in RP1 mice because none of these animals developed leukemia. DNA was obtained from cryopreserved splenic APL cells from animals in this study, as well as previously banked APL specimens from PR, PRxRP3, or irradiated PR animals (PR+XRT). which significantly narrowed the previously defined deleted region, which spanned 21 Mb (including 474 genes/ESTs). 6 Importantly, PU.1 is on the minimally deleted region in all deletions identified by aCGH; the CD44 and WT1 genes fall outside this minimally deleted region, corroborating the observation that haploinsufficiency for PU.1 is relevant for APL penetrance, while haploinsufficiency for CD44 or WT1 is not ( Figure 2E ).
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Del(2) has also been described in AML syndromes induced by irradiation, 6 benzene, 17 and overexpression of Hox genes in bone marrow progenitors. 18 Although del(2) appears to facilitate APL/AML progression, it is not required, since many PML-RARα expressing mice do not have it. 4, 7, 19 The genetic differences between bcr-1 and bcr-3 isoforms of RARα-PML in doubly transgenic mice may contribute to their different abilities to facilitate del (2) . The alpha
For personal use only. on November 12, 2017. by guest www.bloodjournal.org From helical domain (AH) and nuclear localization signal (NLS) of PML are present in the bcr-3 isoform, but not in the bcr-1 isoform of RARα-PML used in these studies ( Figure 1A ). These domains are expressed from both the PR1 and the RP3 transgenes in PRxRP3 mice, while they are present only in the PR1 transgene in PR1xRP1 mice ( Figure 1A) .
Although the relative levels of mRNA expression were similar between the RP3 and RP1 transgenes, small differences in gene dosage could also potentially contribute to differences in disease penetrance between the models. We think that this is unlikely, since two different bcr-3
RARα-PML transgene insertions (with different expression levels) both increased disease penetrance. 4 While the mechanism is not yet clear, our data shows that the additional genetic information contained in the RP3 cDNA may be relevant for APL pathogenesis and the acquisition of del(2). However, it remains possible that the ability of RP3 to increase leukemia penetrance in the PR1xRP3 mice could reflect a non-physiologic interaction between PR1 and RP3.
APL patients expressing a bcr-3 isoform of PML-RARα appear to have additional cytogenetic changes compared to patients expressing the bcr-1 isoform, 20 but this finding is controversial. [21] [22] [23] Our results also suggest that the expression of a bcr-3 isoform of RARα-PML (RP3) may facilitate the acquisition of cytogenetic changes, predominantly manifested by the frequent acquisition of del(2) in mice. The mechanism by which RP3 facilitates the interstitial deletion of chromosome 2 is unknown, but the study of this mechanism may provide valuable insights into the ways by which cytogenetic changes involving chromosomal copy number may occur in some AML patients.
For identifies the minimally deleted region (MDR) defined by aCGH. PU.1 is located within the aCGH defined MDR, while CD44 and WT1 genes are located distal to the telomeric border.
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